

## Major, Solco Healthcare, and Teva – Recall of Valsartan and Valsartan/Hydrochlorothiazide Products

- On July 16, 2018, [Teva](#) announced a voluntary recall of valsartan and valsartan/hydrochlorothiazide (HCTZ) tablets due to an impurity, N-nitrosodimethylamine (NDMA).
  - Products manufactured by [Solco Healthcare](#) and [Major](#) are also impacted by the recall.
- The recalled products are as follows:

| Manufacturer     | Product Name   |
|------------------|--|
| Solco Healthcare | Valsartan tablets 40 mg, 80 mg, 160 mg, and 320 mg tablets   |
|                  | Valsartan/HCTZ 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg tablets |
| Major            | Valsartan 80 mg and 160 mg tablets   |
| Teva             | Valsartan 40 mg, 80 mg, 160 mg, and 320 mg tablets   |
|                  | Valsartan/HCTZ 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg tablets |

- [Valsartan](#) and [valsartan/HCTZ](#) are indicated for the treatment of hypertension.
  - Valsartan is also indicated for the treatment of heart failure (NYHA class II – IV), and to reduce cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction.
- NDMA is classified as a probable human carcinogen. The presence of NDMA was unexpected and is thought to be related to changes in the way the active substance was manufactured.
  - The FDA review is ongoing and has included investigating the levels of NDMA in the recalled products, assessing the possible effect on patients who have been taking them, and what measures can be taken to reduce or eliminate the impurity from future batches produced by the company.
- [FDA recommendations](#):
  - Patients should contact their healthcare professional if their medicine is included in this recall to discuss their treatment, which may include another valsartan product not affected by this recall or an alternative treatment option.
  - Patients taking the recalled valsartan-containing products should continue taking their medicine until they have a replacement product.
  - Patients should contact their physician or healthcare provider if they believe they have experienced any problem that may be related to using the recalled product.

- For further information regarding this recall, contact the specific company listed below.
  - Major: **1-800-616-2471**
  - Teva: **1-888-838-2872**
  - Solco Healthcare: **1-866-931-9829**



OptumRx<sup>®</sup> specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum<sup>®</sup> company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum<sup>®</sup> trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews<sup>®</sup> is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.